Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
Northwest Biotherapeutics (OTCQB:NWBO), a biotechnology company developing DCVax庐 personalized immune therapies for solid tumor cancers, has announced the passing of its Senior Vice President and General Counsel, Mr. Les Goldman, due to a stroke.
The company, which focuses on developing personalized immunotherapy products, has completed a 331-patient Phase III trial of DCVax-L for glioblastoma (GBM) and submitted a MAA for commercial approval in the UK. Additionally, NWBO has completed a 40-patient Phase I trial of DCVax-Direct for inoperable solid tumor cancers and plans to pursue Phase II trials this year.
Northwest Biotherapeutics (OTCQB:NWBO), societ脿 biotecnologica che sviluppa terapie immunitarie personalizzate DCVax庐 per tumori solidi, ha annunciato la scomparsa del suo Senior Vice President e General Counsel, Mr. Les Goldman, a seguito di un ictus.
La societ脿, focalizzata su prodotti di immunoterapia personalizzata, ha completato un trial di fase III su 331 pazienti con DCVax-L per il glioblastoma (GBM) e ha presentato una MAA per l'approvazione commerciale nel Regno Unito. Inoltre, NWBO ha concluso un trial di fase I su 40 pazienti con DCVax-Direct per tumori solidi inoperabili e intende avviare studi di fase II nel corso dell'anno.
Northwest Biotherapeutics (OTCQB:NWBO), una biotecnol贸gica que desarrolla terapias inmunol贸gicas personalizadas DCVax庐 para tumores s贸lidos, ha anunciado el fallecimiento de su Senior Vice President y General Counsel, Mr. Les Goldman, a causa de un ictus.
La compa帽铆a, centrada en el desarrollo de productos de inmunoterapia personalizada, complet贸 un ensayo fase III con 331 pacientes de DCVax-L para glioblastoma (GBM) y present贸 una MAA para la aprobaci贸n comercial en el Reino Unido. Adem谩s, NWBO ha finalizado un ensayo fase I con 40 pacientes de DCVax-Direct para tumores s贸lidos inoperables y planea iniciar ensayos de fase II este a帽o.
Northwest Biotherapeutics (OTCQB:NWBO), 瓿犿槙膦呾枒 雽�靸� 毵烄钉順� 氅挫棴旃橂鞝� DCVax庐毳� 臧滊皽頃橂姅 靸濍獏瓿淀暀 旮办梾鞚�, 靹犾瀯 攵�靷灔 瓴� 氩曤齑濌磩鞚� Les Goldman 鞌�臧� 雵岇「欷戩溂搿� 氤勳劯頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟.
臧滌澑毵烄钉順� 氅挫棴旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞚� 須岇偓電� 甑愲靹疙彫膦�(GBM) 旃橂鞖� DCVax-L鞐� 雽�頃� 331氇� 雽�靸侅潣 3靸� 鞛勳儊鞁滍棙鞚� 鞕勲頃橁碃 鞓侁淡鞐愳劀 靸侅梾 項堦皜毳� 鞙勴暅 MAA毳� 鞝滌稖頄堨姷雼堧嫟. 霕愴暅 NWBO電� 靾橃垹 攵堦皜 瓿犿槙鞎� 雽�靸� DCVax-Direct鞚� 40氇� 雽�靸� 1靸� 鞛勳儊鞁滍棙鞚� 毵堨长鞙茧┌, 鞓暣 2靸� 鞁滍棙鞚� 於旍頃� 瓿勴殟鞛呺媹雼�.
Northwest Biotherapeutics (OTCQB:NWBO), une soci茅t茅 de biotechnologie d茅veloppant des th茅rapies immunitaires personnalis茅es DCVax庐 pour les tumeurs solides, a annonc茅 le d茅c猫s de son Senior Vice President et General Counsel, M. Les Goldman, 脿 la suite d'un AVC.
La soci茅t茅, qui se consacre au d茅veloppement de produits d'immunoth茅rapie personnalis茅e, a achev茅 un essai de phase III portant sur 331 patients de DCVax-L pour le glioblastome (GBM) et a d茅pos茅 une MAA pour obtenir l'autorisation commerciale au Royaume-Uni. De plus, NWBO a termin茅 un essai de phase I portant sur 40 patients de DCVax-Direct pour des tumeurs solides inop茅rables et pr茅voit de lancer des essais de phase II cette ann茅e.
Northwest Biotherapeutics (OTCQB:NWBO), ein Biotechnologieunternehmen, das personalisierte DCVax庐-Immuntherapien f眉r solide Tumoren entwickelt, hat den Tod seines Senior Vice President und General Counsel, Mr. Les Goldman, infolge eines Schlaganfalls bekanntgegeben.
Das Unternehmen, das sich auf die Entwicklung personalisierter Immuntherapien konzentriert, hat eine Phase-III-Studie mit 331 Patienten zu DCVax-L bei Glioblastom (GBM) abgeschlossen und eine MAA zur kommerziellen Zulassung im Vereinigten K枚nigreich eingereicht. Au脽erdem hat NWBO eine Phase-I-Studie mit 40 Patienten zu DCVax-Direct bei inoperablen soliden Tumoren abgeschlossen und plant, dieses Jahr Phase-II-Studien durchzuf眉hren.
- None.
- None.
The Company greatly appreciates Mr. Goldman's many years of intensive work on behalf of the Company, its shareholders and cancer patients. The Company extends its deepest condolences to the Goldman family. Mr. Goldman's duties are being assumed by other members of the Company's management team at this time.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products that are designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has a broad platform technology for DCVax庐聽dendritic cell-based vaccines.聽The Company's lead program involves DCVax庐-L treatment for glioblastoma (GBM). GBM is the most aggressive and lethal form of primary brain cancer, and is an "orphan disease." The Company has completed a 331-patient Phase III trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning plans for DCVax庐 are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those projected in any forward-looking statement. Readers should not rely upon forward-looking statements. There are a number of important factors that could cause actual results to differ materially from those anticipated, including, without limitation, risks related to delays or uncertainties in regulatory processes and decisions, risks related to the Company's ability to achieve timely performance of third parties, risks related to whether the Company's products will be viewed as demonstrating safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual plans, results or timelines to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
CONTACT
Northwest Biotherapeutics
Dave Innes
804-513-6758
[email protected]
View original content to download multimedia:
SOURCE Northwest Biotherapeutics
FAQ
Who was Les Goldman at Northwest Biotherapeutics (NWBO)?
What is the current status of Northwest Biotherapeutics' DCVax-L treatment?
What clinical trials has Northwest Biotherapeutics (NWBO) completed?
Who will take over Les Goldman's responsibilities at NWBO?
What are Northwest Biotherapeutics' main products under development?
